Rockville, Maryland — October 29, 2026 Fact.MR projects the global health economics and outcomes research (HEOR) services market to increase from USD 2.8 billion in 2026 to USD 7.9 billion by 2036, registering a compound annual growth rate (CAGR) of 10.9% over the forecast period. The market, valued at USD 2.5 billion in 2025, is expected to create an absolute dollar opportunity of USD 5.1 billion between 2026 and 2036.
The expansion reflects growing demand for evidence that connects clinical outcomes with treatment costs, affordability, and reimbursement requirements. Pharmaceutical manufacturers, contract research organizations (CROs), and healthcare stakeholders increasingly require health economic assessments and outcomes research to support pricing decisions, market access, and health technology assessment (HTA) submissions.
According to Fact.MR, the competitive landscape includes IQVIA Holdings Inc., ICON plc, Syneos Health, Inc., Parexel International Corporation, Cytel Inc., RTI Health Solutions, Oracle Corporation (Oracle Life Sciences), Costello Medical, and Axtria Inc. These providers offer relevant capabilities spanning health economics, economic modeling, real-world evidence, and market access.
Get detailed market forecasts, competitive benchmarking, and pricing trends:
Key Takeaways: Health Economics and Outcomes Research Services Market
- Market valuation: USD 2.8 billion in 2026.
- Forecast market value: USD 7.9 billion by 2036.
- Growth rate: 10.9% CAGR from 2026 to 2036.
- Leading service offering: Health Economics Studies, with a projected 39.0% share in 2026.
- Leading application: Cost-effectiveness Analysis, accounting for an anticipated 36.0% share in 2026.
- Leading end user: Pharmaceutical Companies, with a projected 41.0% share in 2026.
- Fastest-growing country in the reported comparison: USA, with a projected 11.8% CAGR through 2036.
Why Is the Health Economics and Outcomes Research Services Market Growing?
The need to demonstrate clinical and economic value is becoming a central consideration in pharmaceutical development and commercialization. Payers increasingly evaluate whether a treatment’s clinical benefits justify its costs and whether its adoption can be supported within healthcare budgets.
This requirement creates demand for health economic studies, cost-effectiveness models, budget impact analysis, and evidence packages tailored to reimbursement decisions. Pharmaceutical companies can use these services to identify evidence gaps earlier and prepare for payer scrutiny before a product reaches the market.
The growing use of real-world evidence is another factor supporting demand. Data collected outside controlled clinical trials can help sponsors assess treatment patterns, patient outcomes, healthcare utilization, and longer-term value. Such evidence can complement clinical trial findings when stakeholders evaluate a therapy’s performance in routine care.
Digital research workflows also offer opportunities to improve evidence synthesis and model testing. AI-assisted literature screening and more efficient evidence management may help research teams organize information and evaluate assumptions. However, data access restrictions, model transparency, and country-specific reimbursement requirements remain important challenges.
Which Market Segments Are Creating the Greatest Opportunities?
Fact.MR identifies several segments shaping demand for HEOR services in 2026.
Health Economics Studies are projected to account for 39.0% of the service-offering segment. These services support treatment valuation, cost-effectiveness modeling, and budget impact analysis, helping pharmaceutical sponsors prepare evidence for payer assessments.
Cost-effectiveness Analysis is expected to represent 36.0% of the application segment. Its importance reflects the need to compare the costs and outcomes of new therapies against existing treatment options when healthcare decision-makers assess value.
Pharmaceutical Companies are projected to account for 41.0% of end-user demand. Their requirements include pricing evidence, reimbursement dossiers, launch planning, and post-launch outcomes evaluation.
By delivery model, Project-based Services are estimated to hold 48.0% of the market, reflecting demand for defined research engagements tied to product launches and reimbursement milestones. Decision Analytic Modeling is forecast to capture 44.0% of the research methodology segment as structured economic comparisons remain important for HTA submissions.
For service providers, these findings highlight opportunities to combine economic modeling, evidence synthesis, and market access support within integrated project offerings.
Which Countries Offer the Strongest Growth Prospects?
Fact.MR’s country-level forecasts identify the USA and Germany as particularly attractive markets for HEOR service providers between 2026 and 2036.
- USA: 11.8% CAGR. Extensive payer networks and demand for budget-impact evidence support opportunities for providers with strong economic modeling and reimbursement capabilities.
- Germany: 11.4% CAGR. Localized comparative evidence and reimbursement requirements create demand for country-specific health economic assessments.
- United Kingdom: 10.9% CAGR. Cost-effectiveness assessments and national reimbursement review processes support demand for tailored evidence packages.
- Canada: 10.5% CAGR. Providers can address the need to translate clinical outcomes into affordability and public-payer evidence.
- France: 10.0% CAGR. Economic assessments and comparisons with established treatment pathways create opportunities for specialized research services.
- Japan: 9.6% CAGR. Sponsors require locally relevant evidence to support pricing and reimbursement decisions.
- Australia: 9.2% CAGR. Clinical and economic evidence remains important for healthcare access assessments.
For companies considering geographic expansion, these projections suggest that local reimbursement expertise should be a key part of market-entry planning. Providers that adapt research methods and evidence packages to national requirements may be better positioned to serve multinational pharmaceutical sponsors.
Who Are the Top Companies in the HEOR Services Market?
Fact.MR identifies nine companies with relevant capabilities in the health economics and outcomes research services market:
- IQVIA Holdings Inc.
- ICON plc
- Syneos Health, Inc.
- Parexel International Corporation
- Cytel Inc.
- RTI Health Solutions
- Oracle Corporation (Oracle Life Sciences)
- Costello Medical
- Axtria Inc.
Competition centers on health economic study design, real-world evidence generation, decision analytic modeling, and market access expertise. Buyers need research partners capable of connecting clinical findings with payer requirements while maintaining transparent assumptions and credible analytical methods.
The report does not establish a numerical market-share ranking for these companies. Their inclusion should therefore be interpreted as identification of relevant market participants, not a ranked assessment of competitive leadership.
What Should Businesses Consider Before Investing in HEOR Services?
For pharmaceutical manufacturers, the projected market expansion highlights the importance of integrating HEOR planning into clinical development and launch preparation. Early planning can help teams identify evidence requirements before pricing and reimbursement discussions begin.
For CROs and specialist research firms, opportunities include developing capabilities in economic modeling, real-world evidence, patient-reported outcomes, and country-specific HTA submissions. Combining these capabilities can help address multiple evidence needs within a single engagement.
Investors and business development teams should evaluate providers based on the relevance of their HEOR expertise, methodological transparency, access to suitable data, and ability to serve different reimbursement environments. The reported market growth provides a basis for assessing demand, but individual company performance will depend on execution and competitive positioning.
Unlock 360° insights for strategic decision making and investment planning / Read the full report:
Explore More Related Studies Published by Fact.MR Research
Enteral Home Use Syringes Market
About Fact.MR
Fact.MR is a market research and consulting firm providing syndicated research, customized research, investment research, and market intelligence across a broad range of industries. Its research coverage includes food and beverage, healthcare, pharmaceuticals, biotechnology, consumer products, chemicals and materials, technology, industrial goods, and packaging.
Fact.MR provides market intelligence designed to help organizations understand market dynamics, emerging opportunities, competitive developments, and changing industry requirements.
Media Contact
Fact.MR
Email: sales@factmr.com
Phone: +1 (628) 251-1583
Website: www.factmr.com
